Medexus Pharmaceuticals Inc. (TSE:MDP - Free Report) - Equities research analysts at Ventum Cap Mkts increased their Q1 2026 earnings per share estimates for shares of Medexus Pharmaceuticals in a note issued to investors on Wednesday, January 22nd. Ventum Cap Mkts analyst M. Czmielewski now expects that the company will earn ($0.09) per share for the quarter, up from their prior estimate of ($0.10). Ventum Cap Mkts currently has a "Strong-Buy" rating on the stock. The consensus estimate for Medexus Pharmaceuticals' current full-year earnings is $0.16 per share. Ventum Cap Mkts also issued estimates for Medexus Pharmaceuticals' Q2 2026 earnings at ($0.06) EPS, Q3 2026 earnings at ($0.01) EPS, Q4 2026 earnings at $0.03 EPS and FY2026 earnings at ($0.12) EPS.
Several other research firms also recently weighed in on MDP. Raymond James raised Medexus Pharmaceuticals from an "outperform" rating to a "strong-buy" rating and set a C$4.00 price target for the company in a research report on Wednesday, January 8th. Leede Financial raised shares of Medexus Pharmaceuticals from a "moderate buy" rating to a "strong-buy" rating in a research note on Wednesday, January 22nd. Alliance Global Partners raised shares of Medexus Pharmaceuticals to a "strong-buy" rating in a research note on Monday, December 23rd. Finally, Stifel Nicolaus lifted their price target on shares of Medexus Pharmaceuticals from C$4.15 to C$4.50 in a report on Tuesday, January 14th. One investment analyst has rated the stock with a buy rating and five have assigned a strong buy rating to the company's stock. According to MarketBeat, the stock has an average rating of "Strong Buy" and a consensus price target of C$5.58.
Get Our Latest Stock Report on MDP
Medexus Pharmaceuticals Price Performance
Medexus Pharmaceuticals stock traded down C$0.32 during trading hours on Monday, hitting C$4.60. The stock had a trading volume of 231,189 shares, compared to its average volume of 152,449. The stock has a market capitalization of C$112.84 million, a price-to-earnings ratio of 92.00 and a beta of 1.96. Medexus Pharmaceuticals has a 1-year low of C$1.47 and a 1-year high of C$5.56. The stock's fifty day moving average is C$3.30 and its two-hundred day moving average is C$2.74.
About Medexus Pharmaceuticals
(
Get Free Report)
Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.
Recommended Stories
Before you consider Medexus Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medexus Pharmaceuticals wasn't on the list.
While Medexus Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
